Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Disease Markers|May 1, 1991
Antibody directed enzyme prodrug therapy (ADEPT): clinical reportK D Bagshawe, S K Sharma, C J Springer, et al.
British Journal of Haematology|September 12, 1998
Inhibited apoptosis and drug resistance in acute myeloid leukaemiaB D Smith, B J Bambach, M S Vala, et al.
Disease Markers|May 1, 1991
Antibody directed enzyme prodrug therapy (ADEPT): a three phase systemS K Sharma, K D Bagshawe, C J Springer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
Cell Biophysics|January 1, 1993
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrugD C Blakey, B E Valcaccia, S East, et al.
The American Journal of Medicine|November 1, 1988
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine casesR B Mitchell, J E Wagner, J E Karp, et al.
Gene Therapy|December 1, 1996
Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapyS M Bailey, R J Knox, S M Hobbs, et al.
Leukemia|October 1, 1988
Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10)W P Vaughan, C I Civin, D D Weisenburger, et al.
British Journal of Cancer|November 1, 1995
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugsD C Blakey, D H Davies, R I Dowell, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compoundsC J Springer, K D Bagshawe, S K Sharma, et al.
Pageof 12